
MannKind (MNKD) Stock Forecast & Price Target
MannKind (MNKD) Analyst Ratings
Bulls say
MannKind is a biopharmaceutical company with a wide range of opportunities in various therapeutics areas, including diabetes, pulmonary hypertension, and chronic kidney disease. The recent positive Phase 1 data for inhaled nintedanib, the approval of the Furoscix autoinjector, and the launch of Afrezza in type 1 diabetes are all indicators of MNKD's potential for success in the market, particularly in the treatment of IPF which presents a compelling long-term opportunity. The company also has a strong license agreement in place for their commercialized product, Afrezza, and has promising options for future pipeline expansion, such as PPF and the potential for additional in-house programs. Additionally, MNKD's recently reported first quarter results may not have met expectations, but they do not change the overall positive outlook for the company's potential revenue streams, collaboration opportunities, and upcoming catalysts. Overall, there is a favorable risk-reward potential for investors, which is reflected in the increase in price target for MNKD.
Bears say
MannKind is facing several risks that may affect its future profitability and stock valuation, including potential issues with commercial execution, clinical trial results, and regulatory approvals. Additionally, the company's reliance on partnerships for the commercialization of its key treatments could limit its control and impact its overall valuation. Despite a discounted cash flow model projecting a $10 stock price, these risks may hinder the company's ability to achieve this target.
This aggregate rating is based on analysts' research of MannKind and is not a guaranteed prediction by Public.com or investment advice.
MannKind (MNKD) Analyst Forecast & Price Prediction
Start investing in MannKind (MNKD)
Order type
Buy in
Order amount
Est. shares
0 shares